With the opening of the 'J.P. Morgan Healthcare Conference', which attracted much attention last year with domestic pharmaceutical and biotech companies announcing the achievement of 'big deals,’ approaching, attention is gathering on what results will be announced this year.

The keywords of this year's event are glucagon-like peptide-1 (GLP-1)--based obesity drugs and antibody-drug conjugates (ADCs), which have risen as hot topics in the global pharmaceutical and bio market.

At the event, domestic pharmaceutical and biotech companies will be presenting their portfolios and holding face-to-face meetings.

#According to industry sources on the 6th, the 43rd JP Morgan Health